However, the top specialists at Blue Fin Vision employ various approaches that may benefit certain patients: Acute Management: Immediate discontinuation of GLP-1 medication when NAION is confirmed Corticosteroid therapy in selected cases Comprehensive cardiovascular risk factor assessment Secondary Prevention: Aggressive management of vascular risk factors Blood pressure optimisation Aspirin therapy consideration Regular monitoring of the unaffected eye Risk Factors and Patient Selection Certain patient populations require particularly careful consideration before initiating GLP-1 therapy: High-Risk Patients: Individuals with pre-existing diabetic retinopathy Patients with poorly controlled diabetes and high HbA1c levels Those with cardiovascular risk factors Elderly patients Individuals with optic nerve head abnormalities The experienced team at Blue Fin Vision collaborates closely with endocrinologists and primary care physicians to ensure appropriate patient selection and monitoring protocols
Looking to the future, Stevanato Group also offers pharma companies long-term support for drug delivery devices through its investment plan to further strengthen the companys supply offering in multicavity tooling, injection moulding and sub-assembly offerings at its locations worldwide
The trends Im seeing are women using GLP-1 medications who have historically struggled with weight loss resistance or hit a wall in their weight loss journeys
GLP-1 therapy is changing the game in the prevention and treatment of many chronic conditions
This is the 5th global regulatory approval after the US, UK, UAE, and Bahrain
This promotes a feeling of fullness and may help with weight management
